World Journal of Surgical Oncology (Feb 2018)

Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung

  • Eisuke Mochizuki,
  • Shun Matsuura,
  • Kyohei Oishi,
  • Koichi Miyashita,
  • Koshiro Ichijyo,
  • Syunya Furukawa,
  • Miyuki Nagaoka,
  • Shinichiro Mikura,
  • Masaru Tsukui,
  • Naoki Koshimizu,
  • Shogo Sakurai,
  • Kazuhiro Asada,
  • Toshihiro Shirai

DOI
https://doi.org/10.1186/s12957-018-1337-2
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background There are few reports about the factor influencing the prognosis of high-grade neuroendocrine carcinoma. In this study, we evaluated surgical outcome of clinical stage I high-grade neuroendocrine carcinoma. Methods Patients who underwent curative surgery for high-grade neuroendocrine tumors of the lung in clinical stage I were included in this study. We retrospectively analyzed 27 consecutive patients. The aim of this study was to clarify the clinical course of the disease after surgery and what factors influence the prognosis. Results Twenty-two patients have small cell carcinoma, and 5 patients have large cell neuroendocrine carcinoma. Patients who could undergo surgery within 60 days after the first visit (p < 0.01) and undergo lobectomy (p < 0.01) and whose pro-gastrin-releasing peptide ≦ 72 pg/ml (p = 0.04) performed good prognosis after surgery. In multivariate analysis, surgery within 60 days and operative procedure were independent factors associated with OS. Conclusion Surgical resection for clinical stage I high-grade neuroendocrine carcinoma of the lung should be performed as early as possible, and better outcome can be obtained with lobectomy than partial resection.

Keywords